Franklin Resources Inc Alnylam Pharmaceuticals, Inc. Transaction History

Franklin Resources Inc

$334 Billion
Q3 2024

A detailed history of Franklin Resources Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 382,973 shares of ALNY stock, worth $90.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

382,973

Previous 382,973 -0.0%

Holding current value

$90.1 Million

Previous $105 Million -0.0%

% of portfolio

0.03%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$233.81 - $287.01 $21.9 Million - $26.9 Million	93,647 Added 32.37%	382,973 $105 Million
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $7.42 Million - $12.8 Million	51,802 Added 21.81%	289,326 $70.3 Million
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $12.7 Million - $17.2 Million	86,596 Added 57.38%	237,524 $35.5 Million
Q4 2023 Feb 09, 2024	BUY	$151.41 - $196.57 $95,993 - $124,625	634 Added 0.42%	150,928 $28.9 Million
Q3 2023 Nov 13, 2023	SELL	$170.77 - $211.65 $12,978 - $16,085	-76 Reduced 0.05%	150,294 $26.6 Million
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $1.93 Million - $2.21 Million	-10,425 Reduced 6.48%	150,370 $28.6 Million
Q1 2023 May 12, 2023	SELL	$182.66 - $235.53 $9,133 - $11,776	-50 Reduced 0.03%	160,795 $32.2 Million
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $287,571 - $374,030	1,550 Added 0.97%	160,845 $38.2 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $441,249 - $738,920	3,185 Added 2.04%	159,295 $31.9 Million
Q2 2022 Aug 11, 2022	SELL	$120.42 - $169.29 $4.28 Million - $6.02 Million	-35,559 Reduced 18.55%	156,110 $22.8 Million
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $2.37 Million - $3.24 Million	-18,638 Reduced 8.86%	191,669 $31.3 Million
Q4 2021 Feb 11, 2022	BUY	$159.56 - $209.29 $9.68 Million - $12.7 Million	60,652 Added 40.53%	210,307 $35.7 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $24.8 Million - $30.3 Million	146,050 Added 4051.32%	149,655 $28.3 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $66,244 - $91,098	515 Added 16.67%	3,605 $611,000
Q1 2021 May 13, 2021	SELL	$126.83 - $175.69 $62,146 - $86,088	-490 Reduced 13.69%	3,090 $436,000
Q4 2020 Feb 10, 2021	SELL	$122.97 - $147.0 $15 Million - $17.9 Million	-121,685 Reduced 97.14%	3,580 $466,000
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $150,396 - $205,373	1,241 Added 1.0%	125,265 $18.2 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $43,142 - $64,766	-414 Reduced 0.33%	124,024 $19.6 Million
Q1 2020 May 13, 2020	SELL	$93.12 - $133.99 $195,365 - $281,111	-2,098 Reduced 1.66%	124,438 $13.5 Million
Q4 2019 Feb 12, 2020	SELL	$74.51 - $124.23 $5.41 Million - $9.02 Million	-72,646 Reduced 36.47%	126,536 $14.6 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $2,481 - $3,073	-35 Reduced 0.02%	199,182 $16 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $8,298 - $11,691	-126 Reduced 0.06%	199,217 $14.5 Million
Q1 2019 May 14, 2019	BUY	$72.76 - $93.45 $14.5 Million - $18.6 Million	199,343 New	199,343 $18.6 Million
Q3 2018 Nov 13, 2018	SELL	$87.52 - $122.67 $6.91 Million - $9.68 Million	-78,900 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $4.11 Million - $5.01 Million	-46,500 Reduced 37.08%	78,900 $7.77 Million
Q1 2018 May 10, 2018	BUY	$115.92 - $148.54 $8.69 Million - $11.1 Million	75,000 Added 148.81%	125,400 $14.9 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $3.51 Million - $4.29 Million	30,680 Added 155.58%	50,400 $6.4 Million
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $1.43 Million - $2.33 Million	19,720	19,720 $2.32 Million

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.9B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account

Franklin Resources Inc Alnylam Pharmaceuticals, Inc. Transaction History